Stock Market Today, March: CytomX Surges on Positive Data
CytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
Knowing what to include helps you prepare quickly. This intro highlights essential categories and a simple framework for an effective emergency budget.
15,405 articlesCytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
Two pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...
Pi Network rolls out major upgrades and a second migration as Kraken opens Pi trading, driving volatility amid Pi Day...
GE Vernova’s stock slid after a mixed Q2 report, with earnings missing estimates but revenue beating forecasts. This ...
A growth stock that surged to lofty heights last year has cooled in 2026, but big buyers keep stepping in as AI capac...
Choosing between broad health care exposure and a concentrated pharma tilt can shape risk, returns, and your overall ...
A powerful, data-driven case for why the healthcare stock rebound 2026 is more than a rumor. Learn how to spot streng...
eXp Realty will enable its agents to syndicate coming soon listings to multiple portals through Zenlist, broadening e...
Powell confirms he will remain as chair pro tem if Warsh is not confirmed by mid-May, delivering a clear answer amid ...
Palantir's journey has been a roller coaster—massive gains, sharp pulls, and ongoing questions. This guide distills w...
As Taysha prepares to share Q4 2025 results, investors search for clarity on cash runway, pipeline progress, and futu...
Nvidia has shown accelerating AI-driven demand that could push the stock higher. This article breaks down why the mar...